Neurocrine Biosciences Inc NBIX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:00 PM EST
92.97quote price arrow down-2.04 (-2.15%)
Volume
684,160
52 week range
72.14 - 136.26

...

Loading . . .

KEY STATS

  • Open94.46
  • Day High95.99
  • Day Low91.35
  • Prev Close95.01
  • 52 Week High136.26
  • 52 Week High Date07/09/20
  • 52 Week Low72.14
  • 52 Week Low Date03/18/20
  • Market Cap8.734B
  • Shares Out93.94M
  • 10 Day Average Volume0.87M
  • Dividend-
  • Dividend Yield-
  • Beta0.84
  • 1 Year % Change-5.58

RATIOS/PROFITABILITY

  • EPS (TTM)4.16
  • P/E (TTM)22.36
  • Fwd P/E (NTM)35.32
  • EBITDA (MRQ)336.10M
  • ROE (MRQ)46.20%
  • Revenue (MRQ)1.046B
  • Gross Margin (MRQ)99.03%
  • Net Margin (MRQ)38.94%
  • Debt To Equity (MRQ)28.23%

EVENTS

  • Earnings Date05/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Neurocrine Biosciences Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2)...
William Rastetter Ph.D.
Chairman
Kevin Gorman Ph.D.
Chief Executive Officer
Matthew Abernethy CPA
Chief Financial Officer
Address
12780 El Camino Real
San Diego, CA
92130-2042
United States